Skip to navigation Skip to content

Clinical Trial: Ozanimod for Cognitive Function

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To improve cognitive function
Number of Subjects: 3
Medication: Ozanimod (RPC-1063)
Location: Iowa
Institutions: PMG Research of McFarland Clinic
1015 Duff Ave., Ames, IA 50010 Contact Information
Jessica Lochart, CCRC
515-956-4159
jessica.lochart@accellacare.com

Funding:

Celgene/BMS

Description

This is a multicenter, single-arm, open-label study to describe the change from baseline in cognitive processing speed in subjects with relapsing multiple sclerosis (RMS) treated with ozanimod HCl 1 mg at 3 years. All enrolled subjects will receive orally administered ozanimod HCl 1 mg.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.